The US Food and Drug Administration has approved dextromethorphan-bupropion (Auvelity), the first for an NMDA receptor antagonist for the treatment of major depressive disorder in adults.
The US Food and Drug Administration (FDA) has approved the first oral N-methyl D-aspartate (NMDA) receptor antagonist for the treatment of major depressive disorder (MDD) in adults, its manufacturer has announced. Auvelity (Axsome Therapeutics) is a proprietary extended-release oral tablet containing dextromethorphan (45 mg) and bupropion (105 mg). It is the "first and only rapid-acting oral medicine approved for the treatment of MDD with labeling of statistically significant antidepressant efficacy compared to placebo starting at one week," the company said in a news release. "The approval of Auvelity represents a milestone in depression treatment…